中国生物制药：附属公司正大天晴1类创新药TQB3205获批临床，拟用于治疗晚期恶性肿瘤

Core Viewpoint - China National Pharmaceutical Group's subsidiary, Changchun Tianqing Pharmaceutical, has received clinical trial approval from the National Medical Products Administration for its innovative drug TQB3205, aimed at treating advanced malignant tumors [1] Group 1: Drug Development - TQB3205 is an oral pan-KRAS inhibitor that effectively suppresses the proliferation of various KRAS-mutant tumor cells [1] - The company plans to accelerate the clinical development of TQB3205 to overcome existing treatment limitations [1] - The goal is to provide new treatment options for a broader range of patients with advanced malignant tumors harboring KRAS mutations [1]